Summary: Current State and Future Directions
The NIH deep phenotyping study represents a paradigm for rigorous biomarker research in ME/CFS (Walitt et al. 2024). Key findings with biomarker potential include:
CSF catecholamine metabolites: Reduced HVA and MHPG correlating with symptoms; invasive but highly specific
B cell population shifts: Increased naïve, decreased switched memory B cells suggesting chronic antigenic stimulation; accessible via routine blood draw
Autonomic parameters: Reduced HRV and baroreflex sensitivity; non-invasive, widely available technology
CPET abnormalities: Reduced VO2peak, chronotropic incompetence, and especially Day 2 decline; objective, physiologically meaningful
Neuroimaging findings: TPJ dysfunction and motor cortex hyperactivity; research tool with potential clinical application
Sex-specific patterns: Different immune markers in men vs. women; critical for biomarker interpretation The path forward requires:
Large-scale replication of NIH study findings
Development of practical, accessible biomarker panels
Validation across diverse patient populations
Integration of multiple biomarker types for improved accuracy
Demonstration of clinical utility for diagnosis and treatment selection The era of “no objective findings” in ME/CFS is ending. The challenge now is translating research discoveries into clinically useful tools that improve patient care.
1 TRPM3 Calcium Channel Panel as a Candidate Multi-Parameter Immune Biomarker
Among emerging biomarker approaches, functional ion channel assays represent a mechanistic strategy: measuring the channel dysfunction (TRPM3 Ca2+ influx), its intermediate consequence (intracellular calcium handling), and the functional outcome (NK cell cytotoxicity) in a single workflow. The proposed panel (Section:trpm3-biomarker-panel) measures: (a) TRPM3-dependent Ca2+ flux amplitude after pregnenolone sulfate stimulation; (b) TRPM7-dependent Ca2+ influx slope; (c) NK cytotoxicity against K562 targets. TRPM3 dysfunction has been validated across six studies including a multi-site validation (Sasso et al. 2026, n=78); TRPM7 dysfunction was reported in a smaller preliminary study (du Preez et al. 2023, n=9) The panel’s diagnostic performance as a composite has not been tested.